

## 11. Pediatric Transplantation

### Table of Contents

#### 11.1 [Pediatric transplantation overview](#)

#### 11.2 [Liver Transplantation](#)

##### 11.2.1 [Pre-transplant evaluation](#)

##### 11.2.2 [Induction therapy](#)

##### 11.2.3 [Maintenance therapy](#)

##### 11.2.4 [Management of rejection](#)

##### 11.2.5 [Transplantation considerations with specific hepatic diseases](#)

##### 11.2.6 [Hepatic Artery Thrombosis](#)

#### 11.3 [Kidney transplantation](#)

##### 11.3.1 [Transplant evaluation](#)

##### 11.3.2 [Induction therapy](#)

##### 11.3.3 [Maintenance therapy](#)

##### 11.3.4 [Management of rejection](#)

##### 11.3.5 [Transplantation considerations with specific renal diseases](#)

#### 11.4 [Heart transplantation](#)

##### 11.4.1 [Induction therapy](#)

##### 11.4.2 [Maintenance therapy](#)

##### 11.4.3 [Management of rejection](#)

##### 11.4.4 [Transplantation in specific cardiac diseases](#)

##### 11.4.5 [Miscellaneous](#)

#### 11.5 [Lung transplantation](#)

##### 11.5.1 [Induction therapy](#)

##### 11.5.2 [Maintenance therapy](#)

##### 11.5.3 [Management of rejection](#)

#### 11.6 [Intestinal transplantation](#)

#### 11.7 [Miscellaneous](#)

##### 11.7.1 [Immunizations](#)

##### 11.7.2 [Posttransplant lymphoproliferative disorder](#)

##### 11.7.3 [Pharmacogenomics](#)

### 11.1 Pediatric transplantation overview

Demirhan S, et al (2023). Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients. *Am J Transplant* 2023; 23(12):1961-1971. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37499799/>

- Retrospective study comparing safety and efficacy of BSA v. body weight dosing in transplant recipients. A majority of patients received body weight dosing. BSA dosing patients had more neutropenia, lymphopenia, and acute kidney injury than body weight dosing patients.

Balani SS, et al (2023). Prevention and management of CMV infection in pediatric solid organ transplant recipients. *Front. Pediatr.* 2023;11:1098434. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986459/>

- Overview of the prevention and treatment of CMV in pediatric solid organ transplants.

Hamdani G, et al (2023). Hypertension in Pediatric Solid Organ Transplant Recipients. *Curr Hypertens*

Rep. 2023;25(5):51-60. Retrieved from: <https://link.springer.com/article/10.1007/s11906-023-01237-5>

- A review article summarizing guidelines and available data for the treatment of hypertension in pediatric transplant recipients

Kindem IA, et al (2023). Optimizing medication adherence with home-monitoring - A feasibility study using capillary microsampling and mHealth in solid organ-transplanted adolescents. *Pediatr Transplant*.

2023;27(7):e14590. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14590>

- Single-center feasibility study of utilizing home-sampling of Tac with a medication-manager application in SOT recipients between the ages of 14-25 at least 6 months post-transplant with stable graft function. By the end of the study, there was a 70% perceived improvement in medication timing-adherence. There were no significant long-term changes in TacCV%.

Liverman R, et al (2023). Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis. *Pediatr Transplant*. 2023;27(4):e14493. Retrieved from:

<https://onlinelibrary.wiley.com/doi/10.1111/ptr.14493>

- Retrospective, single-center cohort study of pediatric kidney, liver, and heart transplant recipients transplanted between January 2010- December 2018. CMV DNAemia was detected in 75 of 275 (27.2%) patients who received prophylaxis (40 cases occurred during prophylaxis and 35 occurred after completion of prophylaxis). The median VGC dose given according to institutional weight-based algorithm was approximately 1.5-fold lower than the manufacturer-recommended dose. Dose reduction due to adverse events was an independent risk factor for breakthrough CMV DNAemia among patients with similar age, CMV risk stratification, starting VGC dose, immunosuppressive therapy, and organ group.

Soneji M, et al (2022). Metronidazole for treatment of norovirus in pediatric transplant recipients. *Pediatric Transplantation*. 2022;26:e14390. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/36087286/>

- Retrospective chart review evaluating the use of metronidazole as a potential treatment option for norovirus in solid organ transplant patients apart from nitazoxanide.

Jarasvaraparn C, et al (2022). Characteristics, risk factors, and outcomes of neutropenia after liver or kidney transplantation in children. *Pediatr Transplant*. 2022;26(1):e14131. Retrieved from:

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/ptr.14131>

- Retrospective, single-center chart review of 100 pediatric liver transplant and 82 pediatric kidney transplant recipients seeking to evaluate characteristics, risk factors, and outcomes of neutropenia after transplant. The incidence of neutropenia within the first year of transplant was higher in kidney recipients compared to liver recipients (54.8% vs 39%). The median number of hospitalizations and infectious complications was significantly higher only in the kidney transplant recipients who developed neutropenia. Predictors of neutropenia in liver transplant recipients included history of upper GI bleeding, weight deficit, pre-transplant ANC, and high or moderate risk CMV status. Female gender predicted neutropenia, while BK virus infection was protective for neutropenia in kidney transplant recipients.

Chaudhuri A, et al (2021). Diarrhea in the pediatric solid organ transplant recipient: a multidisciplinary approach to diagnosis and management. *Pediatr Transplant*. 2021;25:e13886.

Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.13886>

- PubMed search of literature regarding diarrhea in pediatric solid organ transplant patients. Reviews infectious and noninfectious etiologies, diagnosis, management, and prevention.

Pilch N, et al (2021). Important considerations for drugs, nutritional, and herbal supplements in pediatric solid organ transplant recipients. *Pediatr Transplant*. 2021;25(1):e13881. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/33142023/>.

- Review of information on generic immunosuppressive drugs, commonly used non-prescription medications, dietary supplements, and herbal supplements in the pediatric solid organ transplant recipient.

Liverman, R, et al (2021). Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient. *Pharmacotherapy*. 2021;00:1-26. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/33151553/>.

- Review article summarizing key aspects of pediatric solid organ transplant pharmacologic management, specifically within the kidney transplant population.

Crowther B (2019). Immunosuppression in Pediatric SOT. Transplantation PedSAP 2019 Book 2. Retrieved from: [https://www.accp.com/docs/bookstore/pedsap/ped2019b2\\_sample.pdf](https://www.accp.com/docs/bookstore/pedsap/ped2019b2_sample.pdf)

- Review of pediatric transplant history, rejection, and immunosuppression.

Fishman JA, et al (2019). *Pneumocystis jiroveci* in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clinical Transplant*. 2019;00:e13587. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/31077616/>

- AST Guidelines on *PJP* treatment and prophylaxis in solid organ transplant patients.

Hirsch HH, et al (2019). BK polyomavirus in solid organ transplantation – Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. 2019;33:e13528. Retrieved from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.13528>

- AST Guidelines on the treatment and management of BK virus in solid organ transplants.

Kotton CN, et al (2018). The Third International Consensus Guidelines on The Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation*. 2018;102(6):900-931. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/29596116/>

- Guidelines for CMV treatment and prophylaxis including monitoring and genotyping in solid organ transplant recipients.

Knackstedt ED, et al (2017). Infections in pediatric solid-organ transplant recipients. *Seminars in Pediatric Surgery* 2017; 26:199-205. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28964474>

- Review of infections and antimicrobial prophylaxis

LaRosa C, et al (2011). Outcomes in pediatric solid-organ transplantation. *Pediatr Transplant*. 2011; 15:128-41. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/21309962>.

- Reviews medical and psychosocial complications and outcomes that arise from pediatric solid organ transplantation.

Agarwal A, et al (2006). Immunosuppression in pediatric solid organ transplantation. *Semin Pediatr Surg*. 2006; 15:142-152. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/16818135>.

- Review of immunosuppressive therapies and their role in pediatric transplantation.

Magee JC, et al (2004). Pediatric transplantation. *Am J Transplant*. 2004; 4:54-71. Retrieved from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2004.00398.x/full>.

- Comprehensive overview of issues related specifically to pediatric transplantation to recognize the many and substantial differences between adults and children

## 11.2 Liver transplantation

Slowk V, et al (2021). Variation in immunosuppression practices among pediatric liver transplant centers- Society of Pediatric Liver Transplantation survey results. *Pediatr Transplant*. 2021;25(2):e13873.

Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/33026158/>.

- Review article describing the IS protocols of pediatric liver transplant centers within the SPLIT to better understand variability and similarities among peer institutions.

Elisofon S, et al (2019). Society of pediatric liver transplantation: current registry status 2011-2018.

*Pediatr Transplant*. 2019;24:e13605. Retrieved from:

<https://onlinelibrary.wiley.com/doi/10.1111/ptr.13605>

- Multicenter, cross-sectional analysis of outcomes from the Studies of Pediatric Liver Transplantation registry data from 2011 to 2018. Reports on indication, transplant type, complications, and immunosuppression used in 1911 patients across 39 centers.

Spada M, et al (2009). Pediatric liver transplantation. *World J Gastroenterol*. 2009; 15: 648-

674. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653434/>.

- Review article that discusses hepatic diseases and focuses on improvements in medical, surgical and anesthetic management, organ availability, immunosuppression, and post-operative complications. Future developments for management of long-term follow-up and prevention of immunosuppression-related complications are also discussed.

### 11.2.1 Pre-transplant Evaluation

Squires RH, et al (2014). Evaluation of the Pediatric Patient for Liver Transplantation: 2014 Practice Guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr*. 2014; 59:112-131. Retrieved from:

<https://www.ncbi.nlm.nih.gov/pubmed/25222807>.

- Current pediatric liver transplant evaluation practice guideline that focuses on pediatric issues at each level of the evaluation process.

### 11.2.2 Induction Therapy

Rogers ME, et al (2023). Anti-thymocyte globulin induction with delayed introduction of tacrolimus preserves renal function in pediatric liver transplant recipients. *Pediatr Transplant*. 2023;27(4):e14509.

Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14509>

- Retrospective single-center cohort study of pediatric liver transplant recipients comparing a renal-sparing (RS) protocol with rATG induction with methylprednisolone, delayed TAC initiation, and lower TAC goals to a standard induction protocol with methylprednisolone induction and early TAC initiation. The RS group had significantly lower mean TAC trough levels at 30 days post-transplant. Renal function was significantly preserved at 6 and 12 months post-LT in the RS group.

Newland DM, et al (2019). Analysis of rabbit anti-lymphocyte globulin vs basiliximab induction in pediatric

liver transplant recipients. *Pediatr Transplant*. 2019;23:e13573. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/petr.13573>.

- Retrospective review of 136 patients comparing induction with either rATG or basiliximab. rATG with or without 2 week steroid taper was associated with higher rates of treated BPAR compared to basiliximab with a 6 month steroid taper. There was no difference in incidence of PTLD, infections, steroid resistant rejection, graft/patient survival, or time to treated BPAR between the groups.

Turner AP, Knechtle SJ (2013). Induction immunosuppression in liver transplantation: a review. *Transpl Int*. 2013; 26:673-683. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/23651083>.

- Review article discussing various induction agents and focuses on basiliximab use in pediatric patients.

Shah A, et al (2006). Induction immunosuppression with rabbit antithymocyte globulin in pediatric liver transplantation. *Liver Transpl*. 2006; 12(8):1210-1214. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/16868953>.

- Results of a retrospective review of 18 pediatric liver transplant recipients with follow-up of 2 years found similar rates of patient and graft survival and decreased rates of rejection compared to literature reports. There was no increased risk of PTLD or CMV in the study population.

Kato T, et al (2006). Pediatric liver transplant with Campath 1H induction—Preliminary report. *Transplant Proc*. 2006; 38(10):3609-3611. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/17175346>.

- Results from a retrospective review of 10 high immunologic risk pediatric liver transplant recipients given alemtuzumab induction therapy. Results were compared to a historical control group that received conventional immunosuppression without induction therapy. Rate of rejection was similar between the groups, but significantly prolonged in the group that received alemtuzumab induction. Alemtuzumab also allowed for lower doses of tacrolimus and steroids for maintenance immunosuppression.

Di Filippo S, et al (2005). Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. *Pediatr Transplant*. 2005; 9(3):373-380. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1399-3046.2005.00303.x>.

- Review article comparing anti-IL-2 induction to anti-lymphocyte antibody induction therapy in pediatric transplant.

Ganschow, et al (2005). Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. *Pediatr Transplant*. 2005; 9:741-745. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/16269045>.

- Results from a long-term follow-up (up to 46 months) of 54 patients found a significant reduction in acute graft rejection as well as similar incidences of chronic rejection, PTLD, graft and patient survival in the treatment group (those patients who received basiliximab induction therapy) compared to the control group. There were no adverse effects observed, which could be related to the antibody treatment.

### 11.2.3 Maintenance Therapy

Kortbeek S, et al (2024); SPLIT Registry. Immunosuppression-Free Life after Pediatric Liver Transplant: A Case-Control Study from the Society of Pediatric Liver Transplant (SPLIT) Registry. *J Pediatr*. 2024;264:113744. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37726087/>

- Case control study using the SPLIT registry assessing pediatric patient outcomes post-liver transplant for patients who had not taken immunosuppression for a minimum of 1 year. Patients were 2:1 matched based on age, sex, primary diagnosis, and time post-liver transplant to controls. Results were similar in terms of growth, laboratory values, rates of PTLD, and rejection.

An S, et al (2023). Safety and Efficacy of Conversion to Once-Daily Tacrolimus from Twice-Daily Tacrolimus in Pediatric Liver Transplant Recipients. *J Pediatr Surg*. 2023 Oct;58(10):2054-2058. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37277238/>.

- Retrospective study assessing conversion of twice daily tacrolimus to once daily tacrolimus in pediatric liver transplant patients. Of the 179 patients converted, 152 had no events, 21 had liver enzyme elevation, 4 had BPAR within 6 months of conversion. Mean tacrolimus level decreased in 3 months following conversion but was overall seen to be safe and effective.

Antala S, et al (2023). Balancing immunosuppression in pediatric liver transplantation: Playing the long game. *Pediatr Transplant*. 2023;27(8):e14575. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14575>

- A review article summarizing the progress that has been made to individualize immunosuppression in pediatric liver transplantation to ensure optimal allograft and recipient health

Ueno T, et al (2022). Long-Term Outcome After Tacrolimus-Related Neurotoxicity in Pediatric Living Donor Liver Transplantation. *Transplant Proc*. 2022;54(2):468-471. 2021.12.036. Retrieved from: <https://www.sciencedirect.com/science/article/pii/S0041134521009568?via%3Dihub>

- Single-center, retrospective analysis of 128 pediatric living donor liver transplant recipients. Six patients (5%) developed tacrolimus-related encephalopathy a median of 9 days after transplant. All patients recovered with conversion to cyclosporine. All patients resumed tacrolimus a median of 8 months from onset. No neurologic complications were observed after resuming tacrolimus.

Leiskau C, et al (2021). Low-dose steroids do make a difference: independent risk factors for impaired linear growth after pediatric liver transplantation. *Pediatr Transplant* 2021;25:e13989. Retrieved from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ptr.13989>

- Single-center, retrospective analysis of liver transplant patients to identify risk factors for impaired growth. Risk factors identified by multivariate analysis for growth impairment were previous growth impairment (P=0.004), graft loss (P=0.006), and prolonged cold ischemic time (P=0.011). Univariate analysis identified continuous low dose steroids (P=0.006) and graft loss (P<0.001) as risk factors for growth impairment. Authors concluded that pre-transplant nutrition is important to optimize growth post-transplant and consideration should be taken for continuation of low dose steroids for long term immunosuppression.

Leiskau C, et al (2018). Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation - A single center matched cohort study. *Pediatr Transplant*. 2018; 22:e13207. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/ptr.13207>.

- Results of a matched case-control trial of tacrolimus plus MMF compared to a historical cohort of patients receiving tacrolimus monotherapy or cyclosporine plus steroids. Incidence of BPAR did not differ between groups. GFR declined at similar rates in all groups. Increased risk of septicemia in tacrolimus plus MMF group. Study was limited by minor reductions in tacrolimus

concentrations.

Ganschow R, et al (2017). Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. *Pediatr Transplant*. 2017; 21(7):epub. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28714558>.

- Results from a 24 month prospective study of 56 pediatric liver transplant recipients. Patients received either basiliximab or no induction and were converted 1-6 months post-transplant from CNI with or without mycophenolate to everolimus with reduced exposure CNI. Recruitment was stopped early due to high rates of PTLD and serious infections related to treatment. eGFR was higher in the everolimus group.

Miloh T, et al (2017). Immunosuppression in Pediatric Liver Transplant Recipients: Unique Aspects. *Liver Transpl*. 2017; 23(2):244-256. Retrieved from: <https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.24677>.

- Addresses immunosuppression options in pediatric patients and issues unique to the pediatric patient population.

Ganschow R, Pollok JM, Jankofsky M, Junge G (2014). The role of everolimus in liver transplantation. *Clin Exp Gastroenterol*. 2014; 7:329-343. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/25214801>.

- This review provides an overview of the efficacy and safety of everolimus-based regimens in liver transplantation in the de novo and maintenance settings, as well as in special populations such as patients with hepatocellular carcinoma recurrence, hepatitis C virus-positive patients, and pediatric transplant recipients.

Kelly D, et al (2013). Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Liver Transpl*. 2013; 19:798-825. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/23836431>.

- Current practice guidelines for long-term medication management after pediatric liver transplantation addressing growth and nutritional management, psychosocial development, neurocognitive function, and adherence. Maintenance immunosuppression, acute and chronic rejection, and the management of adverse effects associated with immunosuppression such as the increased risk for diabetes, hyperlipidemia, hypertension, obesity, and metabolic syndrome are discussed.

Kelly D (2011). Safety and efficacy of tacrolimus in pediatric liver recipients. *Pediatr Transpl*. 2011; 15:19-24. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/21176018>.

- This review provides an overview of studies indicating patients treated initially with tacrolimus compared with cyclosporine have shown significantly lower incidences of rejection, hypertension, hyperlipidemia and cosmetic side effects.

Hasenbein W, et al (2006). Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. *Pediatr Transpl*. 2006; 10:938-942. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/17096762>.

- Retrospective analysis of 129 children on either cyclosporine (n=87) or tacrolimus (n=42) monotherapy to assess the advantages and disadvantages of both drugs at least five years post liver transplantation. There was no significant difference in the calculated glomerular

filtration rate between children on cyclosporine and tacrolimus; cosmetic changes were found in more than one-third of the patients on cyclosporine and in 4.8% of the patients receiving tacrolimus; quality of life was excellent in both groups per self-assessment.

Kelly D, et al (2004). Tacrolimus and steroids versus ciclosporin microemulsion, steroids and azathioprine in children undergoing liver transplantation: randomized European multicentre trial. *Lancet*. 2004; 364:1054-1061. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/15380964>.

- Multicenter, open-label, parallel-group, randomized study compared a dual tacrolimus regimen with a cyclosporine-based triple immunosuppressant regimen pediatric liver transplant recipients. There was no difference between treatment groups with respect to patient survival or graft survival at month 12 after transplant. The acute rejection free rate at study end (Kaplan-Meier method) was 55.5% for patients on tacrolimus and 40.2% for patients on ciclosporin microemulsion (p=0.0288). Incidence of adverse events did not differ between groups.

#### 11.2.4 Management of Rejection

Dehghani SM, et al (2017). Acute Hepatic Allograft Rejection in Pediatric Recipients: Independent Factors. *Int J Organ Transplant Med*. 2017; 8(4):203-206. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756902/>.

- Retrospective review of 47 liver transplant recipients to identify risk factors for rejection. No suspected risk factor (recipient blood group, sex, age, familial history of disease, receipt of drugs/blood products, type of donor, Child score/class) were associated with development of ACR.

Martin SR, et al (2004). Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. *Pediatric Transplant*. 2004; 8:273-283. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/15176966>.

- Data from the 1092 patients who have received a first liver transplant since 1995 were analyzed for factors influencing patient survival, graft survival and acute rejection. Infection was the single most important cause of death and was a contributing cause in 39%, particularly with bacterial or fungal organisms. Risk factors for graft loss included fulminant liver failure and cadaveric technical variant grafts. Initial immunosuppression with tacrolimus reduced the probability of rejection (RR = 0.62, p < 0.05).

#### 11.2.5 Transplantation considerations with specific hepatic diseases

Vasudevan AK, et al (2023). Outcomes of pediatric liver transplantation for progressive familial intrahepatic cholestasis. *Pediatr Transplant*. 2023;27(8):e14600. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14600>

- A prospective review of pediatric liver transplant recipients with progressive familial intrahepatic cholestasis and the impact on short and long-term outcomes.

Mieli-Vergani G, et al (2018). Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. *J Pediatr Gastroenterol Nutr*. 2018; 66(2):345-360. Retrieved from: <https://insights.ovid.com/crossref?an=00005176-201802000-00033>.

- Review of autoimmune hepatitis and autoimmune sclerosing cholangitis, and the role of liver transplantation in management.



Blackburn PR, et al (2017). Maple syrup urine disease: mechanisms and management. *The Application of Clinical Genetics*. 2017;10:57-66. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593394/>

- Overview of MSUD and management including fluid and nutrition requirements.

Sundaram SS, et al (2017). Biliary atresia: indication and timing of liver transplantation and optimization of pretransplant care. *Liver Transplantation*. 2017; 23:96-109. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27650268>.

- Review article which discusses timing of liver transplantation in children with biliary atresia, including a specific discussion for the multidisciplinary team regarding optimization of nutrition and growth prior to transplantation is included. Information on management of complications such as portal hypertension and spontaneous bacterial peritonitis prior to transplantation is also provided.

Oishi K, et al (2016). Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management. *Pediatr Transplant*. 2016; 20:756-69. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27329540>.

- Review article that discusses the use of liver transplantation for various inborn errors of metabolism, including, but not limited to, urea cycle disorders, alpha-1 antitrypsin deficiency, cystic fibrosis, and Wilson disease. Medical management after liver transplantation in these complex disorders is also discussed.

Liberal R, et al (2016). Recurrence of autoimmune liver disease and inflammatory bowel disease after pediatric liver transplantation. *Liver Transpl*. 2016; 22:1275-1283. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27257963>.

- Review article describing incidence of disease in pediatric liver transplant patients who receive transplants for autoimmune liver diseases. Considerations for immunosuppression are discussed.

### 11.2.6 Hepatic Artery Thrombosis

Feldman K, et al (2022). Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation. *Pediatric Transplant*. 2023;00:e14516. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37550273/>

- Overview of incidence and prevention of HAT in pediatric liver transplants. This study showed that aspirin used for HAT prophylaxis post-transplant decreased incidence of HAT more so than patients that received other anticoagulants and antiplatelet agents.

Craig-Schapiro R, et al (2021). Bivalrudin for the prevention of hepatic artery thrombosis in pediatric liver transplantation. *Pediatr Transplant*. 2021;25:e14608. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/petr.14068>

- Single patient case-report of a unique use of bivalrudin in a 9 month old male who had undergone two liver transplants and developed hepatic artery thrombosis (HAT) due to a hypercoagulable state. The patient had a third liver transplant with an intra- and peri-operative bivalrudin infusion of 0.3mg/kg/hour with an intra-operative goal aPTT of 60-80 seconds and activated clotting time of 200-300 seconds and a post-operative goal of aPTT of 80-100 seconds. The patient was converted to therapeutic enoxaparin and then eventually prophylactic enoxaparin and at 1.5 years follow up, the patient has normal graft function and patent hepatic vasculature.

Channaoui A, Tambucci R, Pire A et al (2021). Management and outcome of hepatic artery thrombosis after pediatric liver transplantation. *Pediatr Transplant*. 2021;25(5):e13938. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/33314551/>.

- Study examining the predisposing factors and outcome of HAT post-LT, including the impact of surgical revisions on survival and biliary complications. Results suggest that HAT should be re-operated if occurring within 7 days post-LT, but not beyond.

### 11.3 Kidney transplantation

Puliyanda DP, Jordan SC (2024). Management of the sensitized pediatric renal transplant candidate. *Pediatr Transplant*. 2024;28(2):e14694. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38400645/>.

- Review article summarizing management of sensitized pediatric patients both prior to transplantation, with strategies to overcome sensitization, and after transplantation with monitoring for allograft rejection and other complications.

Seeman T, et al (2023). Hypertension in pediatric kidney transplantation. *Pediatr Transplant*. 2023;27(5):e14522. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14522>

- A review article summarizing guidelines and data in the management of hypertension in pediatric renal transplant recipients

Baskin E, et al (2023). Long-term effect of eplerenone treatment in children with chronic allograft nephropathy. *Pediatr Transplant*. 2023;27(6):e14557. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14557>

- Prospective randomized single-center study with pediatric renal transplant recipients with biopsy-proven chronic allograft nephropathy, eGFR > 40 mL/min per 1.73 m<sup>2</sup>, and with a significant proteinuria randomized to receive eplerenone or not receive eplerenone for 3 years. The eplerenone group had increased eGFR, lower protein-creatinine ratio, and did not have an increased incidence of hyperkalemia.

Buder K et al (2020). Current practice of antithrombotic prophylaxis in pediatric kidney transplantation – results of an international survey on behalf of the European Society for Paediatric Nephrology. *Pediatr Transplant* 2020;24(7):e13799. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.13799>

- Online survey by the European Society of Pediatric Nephrology to evaluate current antithrombotic practices in pediatric kidney transplant patients. 80 transplant centers in 37 countries reported that 96% of centers do antithrombotic prophylaxis. Medications of choice were LMWH (89%), UFH (69%), or aspirin (55%). 51% used single drug therapy and 48% used combination therapy. Authors concluded that UFH is preferred for early post-operative prophylaxis and aspirin is preferred for maintenance prophylaxis.

Hindka A, Huynh D, Verghese P (2021). Dapsone- induced methemoglobinemia in pediatrics post-renal transplant. *Pediatr Transplant*. 2021;25:e13921. Retrieved from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ptr.13921>

- Retrospective review of 31 pediatric kidney transplant recipients who received dapsone at any point post-transplant. Half of included patients were not screened for methemoglobinemia, and of those screened, 77% had acquired methemoglobinemia. Patients on dapsone also experienced more anemia. Authors concluded that patients on dapsone should regularly have hemoglobin and

methemoglobin tested.

Bapistella S, et al (2021). Prophylactic antithrombotic management in adult and pediatric kidney transplantation: a systematic review and meta-analysis. *Pediatr Transplant*. 2021;25:e14021.

Retrieved from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ptr.14021>

- Meta-analysis of 6 pediatric studies (N= 955) evaluating antithrombotic prophylaxis in kidney transplant recipients by looking at a primary outcome of renal graft thrombosis (RGT). 1/6 studies used oral low-dose aspirin, 4/6 studies used heparin IV or SQ, and 1/6 studies used dual therapy with heparin and aspirin. The incidence of RGT was 2.4% in the prophylaxis patients and 11.1% in the control patients. For prophylaxis compared to control groups, the RR was 0.19 [95% CI 0.07-0.54]. However, given poor data quality and lack of consistent protocols between studies, the authors cannot give a recommendation to use or not use antithrombotic prophylaxis in the pediatric kidney transplant population.

Seeman T, Feber J (2021). Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension? *Pediatric Nephrology*. 2021;36,539-549. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/32060819/>.

- Educational review summarizing the current evidence about the effects of ACEI and CCB in pediatric renal transplant recipients.

Mosca M, Lion-Lambert M, Blenaine et al.(2020) Association between 25(OH) vitamin D and graft survival in renal transplanted children (2020). *Pediatr Transplant*. 2020;24(7):e13809. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/32845557/>.

- Retrospective cohort study which assessed the association between vitamin D status and the occurrence of renal rejection which showed that vitamin D levels at 3 months are not associated with lower mGFR or a higher rejection rate at 1 year in children as opposed to adult recipients.

Herbert SA, et al (2017). Special Considerations in Pediatric Kidney Transplantation. *Adv Chronic Kidney Dis*. 2017; 24(6):398-404. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/29229171-special-considerations-in-pediatric-kidney-transplantation/>.

- Review presents a comprehensive discussion of the unique issues in pediatric renal transplantation.

Kasiske BL, et al (2009). KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. *Am J Transplant*. 2009; 9 (Suppl 3): S1-155. Retrieved from:

<https://www.ncbi.nlm.nih.gov/pubmed/19845597>.

- Clinical practice guideline on the monitoring, management, and treatment of kidney transplant recipients intended to assist the practitioner caring for adults and children after kidney transplantation. Includes joint pediatric and adult recommendations and does not highlight specific pediatric recommendations.

### 11.3.1 Transplant Evaluation

Chadban SJ, Ahn C, Axelrod DA, et al (2020). KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. *Transplantation*. 2020;104(4S1 Suppl 1):S11-S103. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/32301874/>

- Updated recommendations for evaluation of kidney transplant patients with pediatric considerations.

### 11.3.2 Induction Therapy

Engen R & Bartosh S (2024). Long-term outcomes of two-dose alemtuzumab induction in pediatric kidney transplantation. *Pediatr Transplant*. 2024;28(3):e14753. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/38623881/>

- Single-center retrospective cohort study of 57 pediatric kidney transplant recipients who received 2 doses of alemtuzumab induction therapy seeking to assess long term graft survival. Only 5 patients received chronic prednisone for kidney disease at high risk of recurrence. Median graft survival was 16.5 years. DSA developed in 36.5% at a median of 944 days. At a follow-up of 7.9 years, incidence of BK DNAemia was 38.6%, incidence of CMV DNAemia was 22.8%, and incidence of EBV DNAemia was 14%. One patient developed PTLD at 13.3 years post-transplant.

Custodio L, et al (2024). Efficacy and safety of single-dose anti-thymocyte globulin versus Basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study.

*Pediatr Transplant*, 2024;28(3):e14713. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38553819/>

- Single-center retrospective cohort study of 227 pediatric kidney transplant recipients who received induction with either rATG 3 mg/kg as a single dose or basiliximab. Patients in the rATG arm had better composite-free (acute rejection, graft loss, death) survival than patients who received basiliximab.

Catibog CJM, Marbella MAG (2022). Outcome of Renal Transplantation in Children Given Rabbit Anti-Thymocyte Globulin (rATG) as Induction Therapy. *Transplant Proc*. 2022;54(2):307-311.2021.12.015.

Retrieved from:

<https://www.sciencedirect.com/science/article/pii/S0041134521009350?via%3Dihub>

- Retrospective single-center study of 11 kidney transplant seeking to evaluate the outcomes of patients receiving rATG for induction. Patient survival was 100% at 6 months, and 90.9% at 1 year. Graft survival was 90.9% at 6 months, and 81.8% at 1 year. Four patients (36.4%) had a glomerular filtration rate of <60 at 1 year. One patient (9.1%) had acute allograft rejection with recurrence of disease. A total of 3 patients (27.3%) developed leukopenia and 4 patients (36.4%) developed thrombocytopenia.

Balani SS, et al (2021). Induction and maintenance immunosuppression in pediatric kidney transplantation- Advances and controversies. *Pediatr Transplant*. 2021;25:e14077. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/34216190/>

- Comprehensive review of the indications, mechanism of action, efficacy, dosing, and side effect profiles of available immunosuppressive agents in pediatric kidney transplantation

Crowson CN, et al (2017). Lymphocyte-depleting induction therapy lowers the risk of acute rejection in African American pediatric kidney transplant recipients. *Pediatr Transplant*. 2017;21:e12823. Retrieved from:

<https://www.ncbi.nlm.nih.gov/pubmed/27699934>.

- The SRTR database was used to assess outcomes in 7884 first-time pediatric kidney transplant patients. Patients who received lymphocyte-depleting induction were compared to those who did not. In African American patients, the risk of acute rejection in 1 year was lower in African American patients who received lymphocyte-depleting induction compared to those who did not. This difference was not significant in non-African American patients.

Velez C, et al (2011). Clinical Description and Evolution of Renal Transplant Pediatric Patients Treated with Alemtuzumab. *Transplant Proc*. 2011; 43(9):3350-3354. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/22099794-clinical-description-and-evolution-of-renal-transplant-pediatric-patients-treated-with-alemtuzumab/>.

- Retrospective, descriptive study of pediatric renal transplant recipients receiving induction immunosuppression with alemtuzumab, daclizumab, and anti-thymocyte globulin. Graft survival at 1 year was better in the patients who received alemtuzumab (87.5%) compared to other induction agents (80%). Incidence of CMV infection was highest in the alemtuzumab group.

Moudgil A, Puliyaanda D (2007). Induction therapy in pediatric renal transplant recipients: an overview. *Paediatr Drugs*. 2007;9:323-341. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/17927304>.

- Review provides an overview of induction therapies for renal transplantation including historic therapies such as total lymphoid irradiation and Minnesota antilymphocyte globulin, and current therapies with polyclonal and monoclonal antibodies and chemical agents, with special emphasis on children.

### 11.3.3 Maintenance Therapy

Kim J, et al (2024). Pharmacokinetics of envarsus in pediatric kidney transplant recipient – phase 1 pilot conversion study. *Pediatr Transplant*, 2024;28(2):e14703. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/38433334/>

- Open-label phase 1 study comparing pharmacokinetics of LCP-tac (Envarsus) and BD-tac (twice daily tacrolimus) in 5 stable pediatric kidney transplant recipients. Six months after conversion from BD-tac to LCP-tac, there were no differences in rejection or eGFR. Maximum concentration was lower and time to maximum concentration was delayed with LCP-tac.

Labriffe M, et al (2023). Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients. *Ther Drug Monit*. 2023;45(5):591-598. Retrieved from: [https://journals.lww.com/drug-monitoring/fulltext/2023/10000/mycophenolate\\_mofetil\\_dose\\_adjustment\\_in\\_pediatric.4.aspx](https://journals.lww.com/drug-monitoring/fulltext/2023/10000/mycophenolate_mofetil_dose_adjustment_in_pediatric.4.aspx)

- Retrospective study utilizing MPA concentrations at T20 min T1 h, and T3 h to estimate MPA AUC in pediatric renal transplant recipients. Overall, only 50% of patients had the first MPA AUC<sub>0–12 h</sub> within the recommended 30–60 mg.h/L range. Due to interindividual variability in MPA exposure, MMF dose adjustment is necessary and efficient at reducing such variability when based on MPA AUC.

Moudgil A, et al (2023). Prevalence of mycophenolate mofetil discontinuation and subsequent outcomes in pediatric kidney transplant recipients: A PNRC study. *Pediatr Transplant*. 2023;00:e14628. Retrieved from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ptr.14628>

- Retrospective analysis of 288 pediatric kidney transplants whose mycophenolate maintenance therapy was discontinued due to side effects. Discontinuation of MMF showed increased risk of alloimmunity, number of hospitalizations and viremias, indicating a need for more optimal MMF regimens to curb side effects while also providing anti-rejection efficacy. Some patients were switched to enteric-coated mycophenolate in the study as part of the discontinuation group which may skew results.

Taha K, et al. (2023). Noninvasive testing for mycophenolate exposure in children with renal transplant using urinary metabolomics. *Pediatr Transplant*. 2023;27(3):e14460. Retrieved from:

<https://onlinelibrary.wiley.com/doi/10.1111/ptr.14460>

- Prospective cohort study of pediatric renal transplant recipients at two centers with urine samples obtained for MPA pharmacokinetic testing. The urinary metabolite classifier exhibited strong

association with MPA AUC by principal component regression ( $r = 0.56$ ,  $p < .001$ ) and PLS ( $r = 0.75$ ,  $p < .001$ ).

Kizilbash SJ, et al (2022). Steroid avoidance/withdrawal and maintenance immunosuppression in pediatric kidney transplantation. *Pediatr Transplant*. 2022;26(2):e14189. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14189>

- Review article that discusses steroid-related toxicities and the safety, efficacy, and benefit of steroid avoidance/withdrawal immunosuppression in pediatric kidney transplant recipients.

Jain A, et al (2022). Steroid-free maintenance immunosuppression using alemtuzumab in pediatric kidney transplantation: Long-term longitudinal follow-up. *Pediatr Transplant*. 2022;26(2):e14173. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14173>

- Retrospective study seeking to examine long-term outcomes with alemtuzumab without steroid maintenance therapy in 71 pediatric kidney transplant recipients. Graft survival at 5 and 10 years was 92.3% and 61.3%, respectively. 16 patients (22.5%) had >3 episodes of t-cell mediated rejection. 16 (22.5%) were treated for antibody-mediated rejection. 23 children developed EBV, 5 developed CMV, and 20 developed BK virus infection. Four (5.6%) developed PTLD. Twenty-two (31.0%) required treatment for neutropenia.

Chandran, M, et al (2021) Impact of once-daily ER-Tac on trough concentration variability in a stable AYA renal transplant recipient cohort. *Pediatr Transplant*. 2021;25(6):e14036. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/34003550/>.

- Retrospective cohort study investigating stable AYA renal transplant recipients converted from IR-Tac to ER-Tac. Out of the 28 patients converted, tacrolimus troughs improved following conversion and was sustained for 24 months while renal function remained stable and BPAR rates were modest.

Balani SS, et al (2021). Induction and maintenance immunosuppression in pediatric kidney transplantation- Advances and controversies. *Pediatric Transplantation*. 2021;25:e14077. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/34216190/>

- Comprehensive review of the indications, mechanism of action, efficacy, dosing, and side effect profiles of available immunosuppressive agents in pediatric kidney transplantation

Albukharim Z, et al (2020). Efficacy and safety of three times daily dosing of tacrolimus in pediatric kidney transplantation patients: A single-center comparative study. *Pediatr Transplant*. 2020;24(6):e13733. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/32463140/>.

- Retrospective, single-center, and comparative cohort study comparing the efficacy and safety of three times daily to twice a day dosing of tacrolimus in pediatric kidney transplant recipients at a major tertiary care transplant center. No significant difference was observed between the two dosing strategies in the time to reach therapeutic trough concentration or in the proportion of patients achieving therapeutic concentrations at day 7.

Lerch C, et al (2017). Belatacept after kidney transplantation in adolescents: a retrospective study. *Transpl Int*. 2017; <https://www.ncbi.nlm.nih.gov/pubmed/28166398>.

- Initial case series of six EBV seropositive adolescent patients (median age 15.5 years) switched to belatacept due to nonadherence to their immunosuppressive regimens a median of 7.5 months after kidney transplant.

Vincenti F, et al (2016). Belatacept and Long-Term Outcomes in Kidney Transplantation. *N Engl Med*. 2016;374:333-43. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/26816011/>

- Final results of BENEFIT study including long-term outcomes of Belatacept in kidney transplant recipients.

Webb NJ, et al (2015). Corticosteroid-free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. *Transplantation*. 2015; 99:1178-1185. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/25539467>.

- 2-year follow-up to the TWIST trial to assess whether improved growth persisted in the longer term. Results showed early corticosteroid withdrawal subjects grew better at 1 year (P = 0.001). At 2 years growth continued to be significantly better in prepubertal subjects (P = 0.004). Bacterial and viral infection was significantly more common in CW subjects at 1 year only. Corticosteroid withdrawal and corticosteroid continuation subjects received similar exposure to both tacrolimus and MMF at 1 and 2 years. No significant difference in patient or graft survival, rejection, estimated glomerular filtration rate, or other adverse events was detected.

Monteverde ML, et al (2012). Conversion to sirolimus in pediatric renal transplant patients: A single-center experience. *Pediatr Transplant*. 2012; 16:582-588. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1399-3046.2012.01697.x>.

- Review of outcomes of 92 pediatric renal transplant recipients converted from CNI to sirolimus immunosuppression after transplant. Median time of conversion post-transplant was 31.6 months. The majority of patients were transitioned due to progressive increasing SCr and biopsy proven chronic allograft nephropathy. Baseline proteinuria and eGFR were determined to be independent risk factors for graft loss. Two patients (1.1%) experienced BPAR. Seventy-three percent of converted patients experienced an adverse event.

Grenda R, et al (2010). A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. *Am J Transplant*. 2010; 10:828-836. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/20420639>.

- Randomized, multicenter study investigated the impact of early steroid withdrawal on mean change in height standard deviation score (SDS) and the safety and efficacy of two immunosuppressive regimens during the first 6 months after transplantation. Children received tacrolimus, MMF, two doses of daclizumab and steroids until day 4 (TAC/MMF/DAC, n=98) or tacrolimus, MMF and standard-dose steroids (TAC/MMF/STR, n=98). Early steroid withdrawal significantly aided growth at 6 months more so in prepubertal than pubertal children. This was accompanied by significantly better lipid and glucose metabolism profiles without increases in graft rejection or loss.

Vincenti F, et al (2010). A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). *Am J Transplant*. 2010;10:535-546. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/20415897/>

- Study evaluating the use of monthly infusion Belatacept as potential option for EBV + kidney transplant recipients with CNI toxicity and/or adherence issues.

Hymes LC, Warshaw BL (2005). Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. *Pediatr Transplant*. 2005; 9:520-522. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/16048606>.

- 4-year experience of 66 children receiving deceased or living donor transplants on a maintenance

immunosuppression regimen of sirolimus 3 mg/m<sup>2</sup> in addition to prednisone and tacrolimus or cyclosporine. Patient survival was 100% and graft survival was 65 of 66. Seven children experienced acute rejection episodes responsive to increased doses of corticosteroid. Sirolimus was discontinued in 20% for adverse events that included poor wound healing and non-infectious pneumonitis. The study concluded a sirolimus-based regimen that is combined with both an interleukin-2 receptor antibody and a calcineurin inhibitor may be excessive immunosuppression for pediatric renal transplant recipients.

Neu AM, et al (2003). Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation a NAPRTCS study. *Pediatr Transplant*. 2003;7:217-22. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/12756047>.

- A NAPRTCS database review looked at primary immunosuppression in 986 pediatric kidney transplant patients. Patients receiving tacrolimus, mycophenolate and steroids were compared to those receiving cyclosporine, mycophenolate, and steroids. At both 1 and 2 year post-transplant, there was no difference in time to first rejection, risk for rejection, or risk for graft failure. However, tacrolimus treated patients were less likely to require antihypertensive therapy at both 1- and 2-years post-transplant. Tacrolimus patients also had higher estimated mean GFR at both 1- and 2-years post-transplant.

#### 11.3.4 Management of Rejection

Ashoor I, et al (2024). Antibody-mediated rejection in pediatric kidney transplant recipients: A report from the Pediatric Nephrology Research Consortium. *Pediatr Transplant*, 2024;28(3). Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38602171/>

- Retrospective cohort analysis of 123 antibody mediated rejection (AMR) episodes in kidney transplant recipients from 14 centers within the Pediatric Nephrology Research Consortium. Patients with an eGFR less than <30 mL/min/1.73 m<sup>2</sup> at time of AMR were more likely to develop the primary composite outcome of graft failure or eGFR <20 mL/min/1.73 m<sup>2</sup> at 12 months after treatment.

Cody EM, et al (2023). Carfilzomib-based antibody mediated rejection therapy in pediatric kidney transplant recipients. *Pediatr Transplant*. 2023;27(7):e14534. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14534>

- A case report of two pediatric renal transplant recipients with AMR and dose-limiting toxicities from bortezomib received carfilzomib for AMR treatment. Carfilzomib was resulted in a reduction or elimination of DSAs but was associated with nephrotoxicity.

Pearl MH, et al (2016). Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection. *Pediatr Nephrol*. 2016;8:1341-1348. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27048228>.

- An examination of seven pediatric kidney transplant recipients to determine the benefit of a therapeutic protocol using bortezomib for refractory C4d positive antibody-mediated rejection. All patients tolerated bortezomib. One patient had allograft loss. Five had improvement of histological findings of AMR, C4d staining, and/or acute cellular rejection. Reduction in HLADSA was more effective for class I than class II.

Ng YW, et al (2015). Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management. *Drugs*. 2015;75:455-472. Retrieved from:



<https://www.ncbi.nlm.nih.gov/pubmed/25813498>.

- A review of the pathophysiology, diagnosis, and management of antibody mediated rejection presented with a pediatric patient case.

Billing H, et al (2012). IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. *Transpl Int*. 2012;11:1165-1173. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/22897111>.

- Antihumoral therapy with IVIG and rituximab significantly reduced or stabilized the progressive loss of transplant function in pediatric patients from 7.6 mL/min/1.73 m<sup>2</sup> to 2.1 mL/min/1.73 m<sup>2</sup> (p=0.0013) with chronic antibody mediated rejection over an observation period of 2 years. This effect was thought to be due to decreased circulating DSA and reduced intrarenal complement activation.

### 11.3.5 Transplantation considerations with specific renal diseases

Peterson C & Jackson R. (2024). Successful use of eculizumab in immediate anca vasculitis recurrence in a pediatric kidney transplant. *Pediatr Transplant*, 28(3). Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38623882/>

- Case report of a 5-year-old male patient who developed recurrent ANC vasculitis post-kidney transplant. After failed treatment attempts with methylprednisolone, rituximab, cyclophosphamide, he remained symptomatic. The patient received eculizumab which was transitioned to ravulizumab with return to baseline of renal function after 5 months of therapy.

Bai J, et al (2023). Incidence, risk factors, and outcomes of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: a systematic review and meta-analysis. *Clin Transplant*. 2023;37(11):e15119. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37725070/>

- Review of FSGS recurrence post-kidney transplant and risk factors associated with recurrence.

Dimitriades V, et al (2023). Hypogammaglobulinemia in pediatric kidney transplant recipients. *Pediatric Nephrology*. 2023;38:1753-1762. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/36178549/>

- Article discussing the incidence of immunoglobulin abnormalities in kidney transplant patients and the correlation with induction and maintenance therapies.

Delbet JD, et al (2023). Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab. *Pediatr Transplant*. 2023;27(5):e14544. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14544>

- A case report of a pediatric renal transplant recipient with post-transplant nephrotic syndrome unresponsive to maintenance immunosuppression, methylprednisolone pulses, daily immunoadsorption, and Obinutuzumab. She was successful treated with daratumumab but had complications of pneumocystis jirovecii pneumonia, CMV viremia, and hypogammaglobulinemia.

Ozcakar Z, et al (2021). Transplantation in pediatric aHUS within the era of eculizumab therapy. *Pediatr Transplant*. 2021;25:e13914. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.13914>

- Retrospective, multi-center review of outcomes of 12 pediatric patients who received a kidney transplant after atypical hemolytic uremic syndrome (aHUS). Eight patients were given prophylactic eculizumab, and 7/8 patients did not have aHUS recurrence after 58.5 months of

follow up. Outcomes regarding kidney transplant outcomes, infections, and eculizumab regimens are reported.

Kang HG, et al (2016). Recurrence and treatment after renal transplantation in children with FSGS. *Biomed Res Int*. 2016; 6832971. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860214/>.

- Review article discussing risk for disease recurrence for children with FSGS who undergo kidney transplantation. Treatment strategies are also presented.

Ounissi M, et al (2011). Malformative uropathies and kidney transplantation. *Transplant Proc*. 2011;43:437-440. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/21440727>.

- Retrospective study describing characteristics and outcomes of 47 patients who underwent kidney transplantation for renal disease caused by congenital anomalies of the kidney and urinary tract. Rejection and graft survival were comparable to patients transplanted for kidney disease from other causes.

Gipson DS, et al (2003). Renal transplantation in children with lupus nephritis. *Am J Kidney Dis*. 2003;41:455-463. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/12552510-renal-transplantation-in-children-with-lupus-nephritis/>.

- Study of the UNOS database comparing 254 children with lupus to 7672 without. Allograft survival was not different between the groups, but in multivariate analysis, patients with lupus were 1.8 times more likely to die than patients without lupus (95% CI, 1.14 to 2.74; P = 0.01).

#### 11.4 Heart Transplantation

Benvenuto V, et al (2023). Use of apixaban in children awaiting heart transplantation. *Pediatr Transplant*. 2024 Feb;28(1):e14632. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37897124/#:~:text=Conclusions%3A%20Careful%20use%20of%20apixaban,increase%20in%20peri%20operative%20bleeding>.

- Retrospective, single centered analysis evaluating patients receiving apixaban prior to heart transplant. This study showed that apixaban can be used safely and effectively prior to transplant without increased risk of peri-operative bleeding. Apixaban provides an alternative option for prophylaxis and treatment of thrombotic events in pediatric heart transplant candidates.

Velleca A, et al (2023). The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 2023;42(5):e1-e141. 2022.10.015. Retrieved from: [https://www.jhltonline.org/article/S1053-2498\(22\)02185-4/fulltext](https://www.jhltonline.org/article/S1053-2498(22)02185-4/fulltext)

- Guidelines for the management of heart transplant recipients with specific pediatric recommendations included.

Hollander S, Ogawa M, Hopper R et al (2020). Treprostinil improves hemodynamics and symptoms in children with mild pulmonary hypertension awaiting heart transplantation. *Pediatr Transplant*. 2020;24(5):e13742. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/32428328/>.

- Single-center retrospective review of all patients listed for HT who received treprostinil during the listing period. Treprostinil significantly decreased PVR (3.8 vs 3.1 WU, P = 0.03), while mLA or mPCW pressure did not change (11 vs 13 mm Hg, P = 0.9). HF symptoms improved in 9/15 (60%) patients without VAD support prior to drug initiation, including 4/10 (40%) who did not receive a VAD any point while awaiting HT.

Dipchand AI (2018). Current state of pediatric cardiac transplantation. *Ann Cardiothorac Surg.* 2018; 7(1): 31–55. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827130/>

- Review of data registries, recipients demographics, waitlist support, outcomes, and immunosuppression.

Conway J, Dipchand AI (2010). Heart transplantation in children. *Pediatr Clin North Am.* 2010;57:353-373. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/20371041>.

- Review article that provides general information on pediatric heart transplantation in children, including indications, pretransplant assessment, transplant surgery, complications, and outcomes.

Canter CE, et al (2007). Indications for Heart Transplantation in Pediatric Heart Disease.

*Circulation.* 2007;115:658-676. Retrieved from: <http://circ.ahajournals.org/content/115/5/658>.

- Guidelines for the development and refinement of indications for heart transplantation for patients with congenital heart disease and pediatric cardiomyopathies in addition to indications for pediatric heart retransplantation.

Rosenthal D, et al (2004). International Society for Heart and Lung Transplantation: Practice Guidelines for Management of Heart Failure in Children. *J Heart Lung Transplant.* 2004; 23(12):1313-1333.

Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/15607659>

#### 11.4.1 Induction Therapy

Ghaleb S, et al (2020). Antithymocyte globulin induction therapy and myocardial complement deposition in pediatric heart transplantation. *Pediatr Transplant* 2021;25:e13998. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/33704881/>

- Single center retrospective study that examined the relationship of induction immunosuppression with ATG and C4d deposition in EMB of pediatric cardiac transplants. It was concluded that C4d deposition is common on EMB up to 1-year post-pediatric cardiac transplant following ATG induction.

Wagner SJ (2019). Less Is More in Post Pediatric Heart Transplant Care. *Ann Thorac Surg.*

2019; 107:165-72. Retrieved from: [https://www.annalsthoracicsurgery.org/article/S0003-4975\(18\)31040-3/fulltext](https://www.annalsthoracicsurgery.org/article/S0003-4975(18)31040-3/fulltext)

- Single center retrospective study of 49 pediatric cardiac recipients compared induction steroids with protocol biopsies to those who receive no steroids or biopsies. No difference in survival, In the group with no steroids or biopsies there was less rejection, less hypertension, and less insulin dependence.

Carlo WF, et al (2019). Comparison of 10-year graft failure rates after induction with basiliximab or antithymocyte globulin in pediatric heart transplant recipients—The influence of race. *Pediatr Transplant.* 2019;23:e13366. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/30735604>

- This study was a retrospective study of 5,464 pediatric heart recipients. Authors concluded that black recipients who received thymoglobulin had improved long-term graft survival compared to those who received basiliximab or no induction

Butts RJ, et al (2018). Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart

transplant recipients: An analysis of the International Society for Heart and Lung Transplantation database. *Pediatr Transplant*. 2018;22:e13190. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/ptr.13190>

- Retrospective study of 3158 pediatric heart recipients who received induction with basiliximab or antithymocyte globulin compared graft survival. Authors concluded antithymocyte globulin is associated with improved late graft survival.

Schweiger M, Zuckermann A, Beiras-Fernandez A, et al (2018). A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients. *Ann Transplant*. 2018;23:322-333. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/29760372>.

- Pediatric heart transplant recipients receiving rATG have an associated improved graft survival compared to patients receiving interleukin-2 receptor antagonists. The benefit of rATG was shown in low-risk patients receiving tacrolimus and mycophenolate mofetil in a steroid-free regimen, patients who were sensitized with pre-formed alloantibodies and/or a positive donor-specific crossmatch, and in ABO-incompatible heart transplant recipients.

Castleberry C, Pruitt E, Ameduri R, et al (2018). Risk Stratification to determine the Impact of Induction Therapy on Survival, Rejection, and Adverse Events after Pediatric Heart Transplant: A Multi-Institutional Study. *J Heart Lung Transplant*. 2018;37(4):458-466. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28619384>.

- Induction therapy with anti-thymocyte antibody (ALA) or interleukin-2 receptor antagonist (IL2-RA) is associated with decreased rejection but did not directly influence survival. Patients deemed low risk may benefit from induction therapy, particularly IL-2RA may be correlated with a decrease in infection and rejection.

Butts R, et al (2017). Effect of Induction Therapy on Graft Survival in Primary Pediatric Heart Transplantation: A Propensity Score Analysis of the UNOS Database. *Transplantation*. 2017;101(6):1228–1233. Retrieved from: <https://www.ncbi.nlm.nih.gov/m/pubmed/27362312/#ft>

- Analysis of 2,792 pediatric heart recipients using UNOS database to investigate the effects of induction immunosuppression on graft survival. No difference was seen in graft survival when comparing patients who received induction to those who did not. In the subgroup analysis, a benefit was seen for patients with a PRA greater than 50% and congenital heart disease.

Ansari et al (2016). Comparison of Basiliximab and Anti-Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis. *J Am Heart Assoc*. 2016;5:e002790. Retrieved from: <https://www.ahajournals.org/doi/10.1161/JAHA.115.002790>

- Analysis of 2,275 pediatric heart recipients using UNOS database to compare long-term mortality between basiliximab and thymoglobulin. Authors concluded basiliximab was associated with increased mortality when compared to thymoglobulin.

Boucek RJ Jr, et al (1999). Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. *J Heart Lung Transplant*. 1999;18:460-469. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/10363691>.

- 461 patients enrolled in the Pediatric Heart Transplant Study Group between January 1993 and December 1995 were divided into three groups based on induction (OKT3, rabbit polyclonal antithymocyte globulin serum [ATS], no induction), evaluated, and

followed for up to 36 months. Overall mortality and death due to rejection was lowest in the ATS group. Induction did not affect cumulative infections, deaths due to infection, or the frequency of malignancies. Cumulative rejection and freedom from rejection death were lowest in centers using ATS.

#### 11.4.2 Maintenance Therapy

Kreienbaum H, et al (2024). mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy. *Pediatr Transplant*. 2024;28(2):e14698. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38433342/>

- Retrospective study examined the effects of everolimus therapy combined with low-dose calcineurin inhibitors. It was concluded that everolimus initiation within the first 14 days after heart transplantation seems to be well tolerated given low incidence of rejection, PTLD, renal failure without evidence of CAV and good overall survival.

Hartje-Dunn C, et al (2024). Medium-term Outcomes in Pediatric Heart Transplant Recipients Managed Using a Steroid Avoidance Immune Suppression Protocol. *Transplantation*. 2024 Jan 1;108(1):e8-e14. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37788365/>.

- Single center review of steroid avoidance protocol in 151 pediatric heart transplant patients without donor specific antibodies and resulting 94% graft survival at 1 year and 87% at 5 years.

Watelle L, et al (2023). Single-drug immunosuppression is associated with noninferior medium-term survival in pediatric heart transplant recipients. *J Heart Lung Transplant*. 2023;42(8):1074-1081. 2023.02.1705. Retrieved from:

<https://www.sciencedirect.com/science/article/pii/S1053249823017722?via%3Dihub>

- Retrospective multicenter international observational cohort non-inferiority study comparing pediatric heart transplant recipients maintained on a least two immunosuppressive medications compared to those maintained on a monotherapy immunosuppressive regimen. Monotherapy regimens were non-inferior for the primary outcome of graft failure, a composite of death, and re-transplantation. There was a lower incidence in the rate of cardiac allograft vasculopathy in the monotherapy cohort.

Almond CS (2023). The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score. *American Heart Journal*. 2023;260:100-112. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/36828201/>

- Study design of current ongoing study evaluating everolimus and low-dose tacrolimus with standard tacrolimus and high-dose mycophenolate dosing.

Newland DM, et al (2023). Assessment of the adverse effects of sirolimus versus everolimus in pediatric heart transplant recipients. *Pediatr Transplant*. 2023;27(3):e14487. Retrieved from:

<https://onlinelibrary.wiley.com/doi/10.1111/ptr.14487>

- Retrospective single-center analysis of 87 pediatric heart transplant recipients who received a PSI between 2009-2020. There was greater increase in HDL cholesterol in SRL cohort compared to EVL cohort. eGFR and HDL cholesterol increased significantly within SRL cohort, triglycerides and glycosylated hemoglobin increased in EVL cohort, and LDL cholesterol and total cholesterol increased in both cohorts.

Rosenthal L, et al (2021). Long-term experience using CNI-free immunosuppression in selected pediatric heart transplant patients. *Pediatr Transplant*. 2021;25(8):e14111. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/34405495/>.

- Retrospective analysis conducted of 129 pediatric heart transplants performed between 1997 and 2015. Fifteen patients with clinically indicated conversion from CNI-based to CNI-free immunosuppression were identified. Survival data, rejection episodes, renal function, post-transplantation lymphoproliferative disorder and CAV, including examination with OCT were analysed. It was concluded that CNI-free immunosuppression based on mTORis is a safe and appropriate strategy for maintenance therapy in selected pediatric patients, as CAV was stabilized and renal function was improved.

Sirota M, et al (2020). Impact of tacrolimus variability on pediatric heart transplant outcomes. *Pediatr Transplant* 2021;25:e14043. <https://doi.org/10.1111/ptr.14043>.

- Single-center retrospective cohort study of pediatric heart transplant recipients describing the prevalence of ETLV and identifying associations with patient-specific factors and poor outcomes. ETLV was associated with a 40% greater risk of CAV, re-HT, or death ( $p = 0.024$ ) and increasing age at transplantation was associated with a 12% increase in the risk of rejection ( $p < 0.001$ ) and a 19% increase in the risk of a composite event ( $p = 0.021$ ).

Lamour JM, et al (2019). Early outcomes for low-risk pediatric heart transplant recipients and steroids avoidance: A multicenter cohort study (Clinical Trials in Organ Transplantation in Children - CTOTC-04). *J Heart Lung Transplant*. 2019; 38(9):972-981. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/31324444-early-outcomes-for-low-risk-pediatric-heart-transplant-recipients-and-steroid-avoidance-a-multicenter-cohort-study-clinical-trials-in-organ-transplantation-in-children-ctotc-04/>.

- Multicenter, prospective cohort study of 240 pediatric heart transplant recipients analyzing 1 year outcomes of patients without pre-transplant DSAs. Patients received thymoglobulin induction and were maintained on tacrolimus and/or mycophenolate. Steroids were not continued beyond 1 week post-transplant. Survival was 94.5%. Freedom from any rejection was 67.5%.

Heble A, et al (2018). Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures. *Pediatr Transplant*. 2018;22:e13093. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811366/>

- Retrospective study of 13 patients continued on mTOR inhibitors in the perioperative period. Authors identified a surgical wound complication in one patient.

Rossano JW, Jefferies JL, Pahl E, et al (2017). Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group. *J Heart Lung Transplant*. 2017;36(4):427-433. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28029575>

- Sirolimus was used in less than 10% of patients at 1 year post-transplant. Overall outcomes of sirolimus treated and non-treated patients were similar with respect to survival and major transplant adverse events. Further study of sirolimus in pediatric heart transplant patients is needed.

Sierra CM, Tan R, Eguchi J, et al (2016). Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients. *Pediatr Transplant*. 2016. [Epub ahead of print]. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27658616>

- Immunosuppression free of CNIs and corticosteroids appears to be a safe alternative in pediatric heart transplant patients with significant renal insufficiency. Furthermore, this strategy can significantly reverse renal insufficiency, even late after transplantation.

Auerbach SR, Kukreja M, Gilbert D, et al (2015). Maintenance steroid use at 30 days post-transplant and outcomes of pediatric heart transplantation: A propensity matched analysis of the Pediatric Heart Transplant Study database. *J Heart Lung Transplant*. 2015;34(8):1066-72. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/?term=Maintenance+steroid+use+at+30+days+post-transplant+and+outcomes+of+pediatric+heart+transplantation%3A+A+propensity+matched+analysis+of+the+Pediatric+Heart+Transplant+Study+database>.

- Maintenance steroid use at 30 days post-transplant was not associated with enhanced graft survival after pediatric heart transplant. Maintenance steroid patients had a higher incidence of rejection with severe hemodynamic compromise and infection. These risks should be taken into consideration when determining maintenance steroid use for pediatric recipients of heart transplants.

Costanzo MR, et al (2010). The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 2010;29:914-956. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/20643330>

- Current practice guidelines for the management of heart transplant recipients. Specific pediatric recommendations are included.

Singh TP, et al (2010). Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. *J Heart Lung Transplant*. 2010;29:517-522. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/20061164>

- 55 patients (median age of 7.1 years) entered a steroid-avoidance immunosuppression protocol consisting of thymoglobulin induction followed by a 2-drug, tacrolimus-based, corticosteroid-free regimen. Freedom from rejection was 92% at 6 months and 87% at 1 year. Post-transplant survival was 91% at 6 months and 88% at 12 and 24 months. There was 1 death due to rejection (antibody-mediated) 8 months after transplantation.

### 11.4.3 Management of Rejection

Deshpande S, et al (2024). Evaluating threshold for donor fraction cell-free DNA using clinically available assay for rejection in pediatric and adult heart transplantation. *Pediatr Transplant*. 2024;28(3):e14708. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38553812/>

- Prospective, observational, non-interventional study aimed to investigate the performance of dd-cfDNA assay at specific cut points in detection of rejection. There was a significant difference for dd-cfDNA between rejection and health samples ( $p < 0.0001$ ). In the pediatric population, the rejection group had a median dd-cfDNA value of 0.93%, while the mean dd-cfDNA value was 0.09% in the healthy group.

Bansal N, et al (2022). Clinical approach to acute cellular rejection from the pediatric heart transplant society. *Pediatr Transplant* 2022;26:e14393. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/36377327/>

- Review of acute cellular rejection and its treatment as well as information regarding center specific approaches to management.

Amdani S, et al (2022). Clinical approach to antibody-mediated rejection from the pediatric heart transplant society. *Pediatr Transplant* 2022;26:e14398. Retrieved from: <https://doi.org/10.1111/ptr.14398>

- Review of antibody mediated rejection and its treatment as well as information regarding center specific approaches to management.

Bearl DW, et al. (2022) Clinical approach to mechanical circulatory support in the transplant patient from the Pediatric Heart Transplant Society. *Pediatr Transplant*. 2022 D;26(8):e14391. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/36377328/>.

- Discussion and compilation of data regarding mechanical circulatory support and immunosuppression adjustments when MCS was utilized as both a bridge and rescue post-transplant.

Fenton M, et al (2022). Daratumumab provides transient response of antibody mediated rejection post pediatric orthotopic heart transplantation. *J Heart Lung Transplant*. 2022 Oct;41(10):1529-1530. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/35864003/>.

- Case report utilizing daratumumab in antibody mediated rejection persisting after methylprednisolone, rituximab, IVIG, and plasmapheresis. After 6-week course of daratumumab, AMR was improved on biopsy.

Das B, Dimas V, Guleserian K, et al (2017). Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. *Pediatr Transplant*. 2017;21(1). Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27862703>

- Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

Taylor D, et al (2010). The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients, task force 2: immunosuppression and rejection. ISHLT Guidelines for the Care of Heart Transplant Recipients. 2010. Retrieved from: [https://www.ishlt.org/ContentDocuments/ISHLT\\_GL\\_TaskForce2\\_110810.pdf](https://www.ishlt.org/ContentDocuments/ISHLT_GL_TaskForce2_110810.pdf)

- Current practice guidelines for the management of immunosuppression and rejection in heart transplant recipients. Specific pediatric recommendations are included.

Thrush PT, et al (2016). A multi-institutional evaluation of antibody-mediated rejection utilizing the Pediatric Heart Transplant Study database: Incidence, therapies and outcomes. *J Heart Lung Transplant*. 2016;35:1497–1504. Retrieved from: <https://www.sciencedirect.com/science/article/pii/S1053249816301929>

- Review of 179 patients and 246 antibody mediated rejection episodes from pediatric heart transplant study database data including incidence, treatment, and outcomes.

#### 11.4.4 Transplantation in specific cardiac diseases

Khan A, et al. Improved heart transplant survival for children with congenital heart disease and heterotaxy



syndrome in the current era: An analysis from the pediatric heart transplant society. *J Heart Lung Transplant*. 2021 Oct;40(10):1153-1163. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/34366230>.

- Evaluation of waitlist survival and post heart transplant outcomes in patients with heterotaxy syndrome compared to those with other congenital heart diseases.

Tabarsi N, et al (2017). Meta-analysis of the effectiveness of heart transplantation in patients with a failing Fontan. *Am J Cardiol*. 2017;119:1269-1274. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28233535>.

- Meta-analysis of 12 studies including 351 patients. Early and mid-term mortality after transplantation in younger patients after Fontan was acceptable and comparable to published mortality data of heart transplantation for other forms of congenital heart disease.

Kirklin JK, et al (2016). Current expectations for cardiac transplantation in patients with congenital heart disease. *World J Pediatr Congenit Heart Surg*. 2016;7:685-695. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/27834759>.

- Review article discussing challenges and outcomes in cardiac transplantation in patients with congenital heart disease, including pediatric mechanical circulatory support.

#### 11.4.5 Miscellaneous

D'Addese L, et al (2023). Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis. *J Heart Lung Transplant*. 2023;42(1):115-123. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/36328858/>.

- Analysis of PTHS database regarding the risk of early aspirin use post heart transplant. Aspirin utilization varied significantly but was associated with worse graft survival and worse freedom from CAV.

Laks JA, et al (2022). Cardiac allograft vasculopathy: A review. *Pediatr Transplant*. 2022;26(3):e14218. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/34985793/>.

- Review article providing an overview of coronary allograft vasculopathy, including a compilation of 148 articles, pathophysiology, prophylaxis, treatment, and future directions.

Krauss A, et al (2023). Successful ABO incompatible heart transplantation after desensitization therapy in an older child. *Pediatr Transplant*. 2023;27(3):e14459. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14459>

- A case report of an older child (5 years 11 months) who received HLA desensitization with rituximab and immunoglobulins and subsequently received an ABO-incompatible heart transplant (recipient blood group O, donor blood group A). The anti-A titer at the time of HTx was 1:16 with post-transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection at 3 years post-transplant.

Sparks JD, et al (2019). New-onset diabetes after pediatric heart transplantation: A review of the Pediatric Heart Transplant Study. *Pediatr Transplant*. 2019;23:e13476. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/31124221>

- Retrospective evaluation of 2185 pediatric heart recipients to identify risk factors and outcomes for new onset diabetes after transplant. Older age, black race, higher BMI, and steroid use were found to increase risk.

Dipchand AI, et al (2018). Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study. *Am J Transplant.* 2018; 18:2163-2174. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.14691>.

- Prospective analysis of 237 pediatric heart transplant recipients on the incidence of newly detected DSAs and their clinical impact. One-third of the patients developed DSAs and most were detected within the first 6 weeks after transplant. This suggests memory response may play a larger role in this population that de novo DSA production. Sensitizing events were determined to be a risk factor for patients developing DSAs post-transplant.

Webber S, et al (2018). Pediatric heart transplantation across a positive crossmatch: First year results from the CTOTC-04 multi-institutional study. *Am J Transplant.* 2018; 18:2148-2162. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.14876>.

- Prospective analysis of 1 year outcomes of sensitized (CDC positive/negative and DSA positive/negative) vs. non-sensitized pediatric heart transplant recipients. Immunosuppression was standardized between groups, with the CDC crossmatch positive patients receiving pre-operative antibody removal, IVIG, and maintenance steroids. The primary endpoint (composite of death, re-transplantation, or rejection with hemodynamic compromise) was not statistically significant between groups (nonsensitized: 6.7%, sensitized crossmatch positive: 18.2%, sensitized crossmatch negative: 10.7%; p=0.2354). Freedom from AMR and ACR was lower in the positive crossmatch group.

## 11.5 Lung Transplantation

Lebecque P, et al (2023). Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?. *Pediatr Pulmonol.* 2023;58(12):3603-3604. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1002/ppul.26682>

- A case report of crushing elexacaftor/tezacaftor/ivacaftor in a pediatric cystic fibrosis patient with improvement in FEV1 and decrease in sweat chloride. This case suggests that crushing the tablet does not compromise clinical efficacy

Spencer H, Shkurka E (2020). Inhaled hypertonic saline after pediatric lung transplant-Caution required? *Pediatr Transplant.* 2020;24(8):e13843. Retrieved from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ptr.13843>.

- Retrospective study aimed to evaluate the effect of inhaled HTS in the acute post-operative period, in pediatric lung transplant patients at a single UK pediatric transplant center. Results provided uncertainty regarding the safety of inhaled HTS after lung transplant as there was a trend of poorer acute outcomes in patients who received HTS compared to a historical control group.

Olsen MC, et al (2017). ECMO for pediatric lung transplantation. *ASAIO Journal.* 2017; Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28125461>.

- Review of use of ECMO and relevant management for pediatric lung transplant recipients before and after transplantation.

Benden C, et al (2017). Pediatric lung transplantation. *J Thorac Dis.* 2017 Aug; 9(8): 2675–2683. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594176/>

- Review article of indications for transplant and management of recipients.

Burcham P, et al (2017). Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis.

*Pediatr Drugs*. 2017;19(4):339-346. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/28547678>

- Review of immunosuppression regimens for adult and pediatric lung recipients with cystic fibrosis.

Goldfarb SB, et al (2016). The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart–Lung Transplantation Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. 2016;35(10):1196-1205. Retrieved from: [https://www.jhltonline.org/article/S1053-2498\(16\)30300-X/fulltext](https://www.jhltonline.org/article/S1053-2498(16)30300-X/fulltext)

- Review of indications, immunosuppression, complications, and survival for pediatric lung transplant.

Solomon M, et al (2010). Pediatric lung transplantation. *Pediatr Clin North Am*. 2010;57:375-391. <https://www.ncbi.nlm.nih.gov/pubmed/20371042>.

- Review article of pediatric lung transplantation including indications, evaluation, operative procedure, graft dysfunction, and outcomes.

Faro A, et al (2007). American Society of Transplantation Executive Summary on Pediatric Lung Transplantation. *Am J Transplant*. 2007;7:285-292. Retrieved from:

<https://www.ncbi.nlm.nih.gov/pubmed/17109726>.

- Consensus statement that highlights challenges in pediatric lung transplantation and provides guidance for the field. Discussion of induction and maintenance immunosuppression are included.

### **11.5.1 Induction**

Sweet SC, et al (2022). CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients. *Am J Transplant*. 2022;22(1):230-244. Retrieved from:

<https://onlinelibrary.wiley.com/doi/10.1111/ajt.16862>

- Randomized, placebo-controlled, double-blind study of pediatric lung transplant recipients, evaluating if rituximab plus rabbit anti-thymocyte globulin induction reduces DSA development and improves outcomes. Of 45 subjects enrolled, 34 were transplanted and 27 randomized to rituximab (n = 15) or placebo (n = 12). No rituximab-treated subjects versus five placebo-treated subjects developed de novo DSA with mean fluorescence intensity >2000. No difference was found in time to the primary composite outcome endpoint (death, bronchiolitis obliterans syndrome [BOS] grade 0-p, obliterative bronchiolitis or listing for retransplant), infection or rejection.

Hayes D, et al (2014). A contemporary analysis of induction immunosuppression in pediatric lung transplant recipients. *Transpl Int*. 2014;27:211-218. Retrieved from:

<https://www.ncbi.nlm.nih.gov/pubmed/24236829>

- A review of UNOS including 330 pediatric lung transplant recipients, 54% of whom received induction therapy. Induction agents included basiliximab, alemtuzumab, antilymphocyte globulin, and antithymocyte globulin. There was not a difference in survival in patients who did or did not receive induction, but there was a trend toward a protective effect with induction.

### **11.5.2 Maintenance**

Hu K, et al (2024). Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels. *Front Pediatr*. 2024;12:1090455. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/38357508/>

- Utilizing a published pharmacokinetic model of tacrolimus in lung transplant and Monte Carlo simulation, the study aimed to optimize the initial tacrolimus dosage in Chinese pediatric lung transplant recipients. The authors made recommendations for initial dosing of tacrolimus based on weight, presence of CYP3A5\*1, and concurrent use with voriconazole.

### 11.5.3 Management of Rejection

Benden C & Wikenheiser-Brokamp, KA (2024). Antibody-mediated rejection (AMR) in pediatric lung transplantation-Current state and future directions. *Pediatr transplant*, 2024;28(2):e14739. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38436533/>

- A review describing antibody-mediated rejection in pediatric lung transplant, current state and knowledge gaps

### 11.6 Intestinal Transplantation

Barau C, et al (2017). Pharmacokinetics of mycophenolic acid and dose optimization in children after intestinal transplantation. *Ther Drug Monit*. 2017;39:37-42. Retrieved from:

<https://www.ncbi.nlm.nih.gov/pubmed/27898598>.

- A pharmacokinetic study of 8 patients who received intestinal transplants. Mycophenolate was initiated at low median starting doses and had to be increased to reach target AUC levels of 30 mg·h·L. Starting doses of 600 mg/m<sup>2</sup> twice daily are recommended based on this evaluation.

Avitzur Y, Grant D (2010). Intestine transplantation in children: update 2010. *Pediatr Clin North Am*. 2010;57:415-431. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/20371045>

- Review article describing pediatric intestinal transplantation, including listing criteria, surgical techniques, management, monitoring, complications, and outcomes.

### 11.7 Miscellaneous

#### 11.7.1 Immunizations

Keutler A, et al (2024). Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation. *Pediatr Transplant*. 2024;28(1):e14687. doi:10.1111/ptr.14687. Retrieved from:

<https://pubmed.ncbi.nlm.nih.gov/38317348/>

- Review article aimed to discuss whether, when, and how live-attenuated MMR vaccines can be administered effectively and safely to pediatric liver transplant recipients. The review included current available literature review to provide guidance on MMR vaccines.

Hartley C, et al (2024). Live-Attenuated Vaccines in Pediatric Solid Organ Transplant. *Vaccines*. 2024;12(4):376. Retrieved from: <https://www.mdpi.com/2076-393X/12/4/376>

- Review article aimed to provide guidance on live-attenuated vaccines (MMR and varicella) in pre-transplant and post-transplant in pediatric patients.

Sintusek P, et al (2024). Antibody persistence of standard versus double three-dose hepatitis B vaccine in liver transplant children: a randomized controlled trial. *Sci Rep*. 2024;14(1):499. Retrieved from:

<https://www.nature.com/articles/s41598-024-51149-w>

- Prospective randomized study investigated anti-HBs persistence after HB vaccination

using two regimens, standard-three-dose (SD) and double-three-dose (DD), at 0, 1 and 6 months in previously immunized pediatric liver transplant recipients who have lost their HB immunity. The authors concluded that SD HB reimmunization regimen is the preferred regimen in maintaining effectively protective anti-HBs levels in children undergoing liver transplantation.

Donà D, et al (2023). Vaccination practices in pediatric transplantation: A survey among member centers of the European reference network TransplantChild. *Pediatr Transplant*. 2023;27(7):e14589. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14589>

- A questionnaire of immunization practices at 26 SOT and 6 HSCT programs. A quarter of centers did not have an on-site protocol for the immunizations. Variations in the time between vaccine administration and admission to the waiting list were reported between the centers, with 2 weeks for inactivated vaccines and variable time (2-4 weeks) for live-attenuated vaccines (LAVs). Almost all sites recommended immunization in the post-transplant period, with a time window of 4-8 months for the inactivated vaccines and 16-24 months for MMR and Varicella vaccines.

Feldman AG, et al (2023). Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. *JAMA Network Open*. 2023;6(10):e2337602. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37824141/>

- Cohort study evaluating the administration of MMR and VZV vaccines in post-liver and kidney transplant recipients. Majority of cohort maintained immunity one year post-vaccination. About 2% of patients developed clinical varicella which resolved within a week. No cases of measles or rubella were reported. No cases of rejection were reported within 1 month of vaccination.

Kitano T et al (2023). Immunogenicity of a quadrivalent human papillomavirus vaccine in pediatric kidney and liver transplant recipients. *Pediatr Transplant*. 2023;27(3):e14476. doi:10.1111/ptr.14476. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.14476>

- A prospective observational single-center study of pediatric renal and liver transplant recipients receiving three doses of the quadrivalent HPV recombinant vaccine. Liver transplant recipients has higher titers and seropositivity rates compared to kidney transplant recipients on multiple immunosuppressive medications.

Crane C, et al (2022). Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients. *Pediatr Nephrol*. 2022;37(2):449-453. doi:10.1007/s00467-021-05256-9. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440151/>

- Evaluation of response of adolescent kidney transplant recipients who received both doses of an mRNA SARS-CoV-2 vaccine. 13 of 25 fully vaccinated patients (52%) had a positive spike antibody. Of those who had an antibody response, fewer had a mycophenolate-containing immunosuppressant regimen than non-responders. There was a trend toward better vaccine response and higher anti-S antibody titers at lower doses of mycophenolate. Three patients with prior COVID-19 infection all had a positive antibody response

Newman AM, et al (2022). Live virus vaccination following pediatric liver transplantation: Outcomes from two academic children's hospitals. *Am J Transplant*. 2022;22(4):1201-1212. doi:10.1111/ajt.16937. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ajt.16937>

- Retrospective cohort study of 204 pediatric liver transplant recipients. 97 received at least one live virus vaccine after transplant. 6 patients who did not receive live virus vaccine after transplant had evidence of vaccine-preventable infection. Rejection rates were the same between those that did and did not receive a live virus vaccine post-transplant. There were no serious adverse events caused by vaccination post-transplant.

Ball M, Liverman R, Serluco A, Yildirim I (2021). Vaccine-induced protection against hepatitis B in pediatric solid organ transplant patients. *Pediatr Transplant*. 2021;25:e13920. Retrieved from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ptr.13920>

- Retrospective review of 381 evaluated and/or transplanted patients to evaluate Hepatitis B virus (HBV) vaccination coverage, seroprotection rates, and factors affecting vaccine immunity. HBV surface antibody (HbsAb) reactivity was 56.7% in the overall population and 53.9% in the patients who had been vaccinated. 73.3% of patients who underwent revaccination due to non-reactive/indeterminate results seroconverted to a reactive HbsAb.

Chen JK, et al (2021). Vaccination in pediatric solid organ transplant: A primer for the immunizing clinician. *Clin Transplant*. 2021;36:e14577. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/34997642/>

- Overview of guidelines for vaccination in pediatric solid organ transplants that provides delineated table on what vaccines to give and when.

Danziger-Isakov L, et al (2019). Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant*. 2019; 33(9):e13563. Retrieved from: <https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.13563>

- AST IDCOP Guidelines for vaccinations

Suresh S, et al (2019). Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018. *Pediatr Transplant*. 2019 Nov;23(7):e13571. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/31497926>

- Guidance by a consortium of experts on the use of live-attenuated viral vaccines after solid organ transplant. Includes recommendations for MMR and VV vaccines.

Dulek DE, de St Maurice A, Halasa NB (2018). Vaccines in pediatric transplant recipients-Past, present, and future. *Pediatr Transplant*. 2018;22(7):e13282. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/30207024/>

- Provides review of recent immunization studies performed in pediatric transplant patients.

Rubin LG, et al (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis*. 2014;58:309-318. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/24421306>

- Evidenced-based guideline for vaccination of immunocompromised adults and children.

### 11.7.2 Posttransplant lymphoproliferative disorder

Mark C, et al (2024). Treatment of Monomorphic Posttransplant Lymphoproliferative Disorder in Pediatric Solid Organ Transplant: A Multicenter Review. *J Pediatr Hematol Oncol*. 2024;46(2):e127-e130. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38145403/>

- Retrospective study evaluated data from 3 Canadian pediatric centers to determine

patient characteristics, treatment approaches, and outcomes for children with monomorphic PTLD. The projected 3-year event-free survival/3-year overall survival was 62% and 77%, respectively. All patient with T/NK-cell PTLD progressed or relapsed and, subsequently, died of disease. No significant difference in outcome between the 2 main chemotherapy regimens (Mature Lymphoma B-96 protocol vs low-dose cyclophosphamide) in patients with B-cell PTLD

Ashoor IF, et al (2024). Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium. *Pediatr Transplant*. 2024;28(3):e14743. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/38566336/>

- Large case series study evaluated the efficacy and safety of rituximab in pediatric kidney transplant recipients with EBV DNAemia to prevent PTLD. Rituximab achieved a short-term reduction in DNA load; however, recurrent DNAemia is common. PTLD occurred in 2 patients (out of 26) at 915 and 1713 days after rituximab treatment

Green M, et al (2024). The IPTA Nashville consensus conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: II-consensus guidelines for prevention. *Pediatr Transplant*. 2024;28(1):e14350. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/36369745/>

- Consensus guidance on immunoprophylaxis and chemoprophylaxis, and pre-emptive strategies in PTLD prevention based on existing literature

Gross TG, et al (2023). Post-transplant lymphoproliferative disease in children, adolescents, and young adults. *Hematol Oncol*. 2023;41 Suppl 1:48-56. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1002/hon.3139>

- A review article summarizing the management of PTLD and treatment strategies following pediatric solid organ transplantation

Devine K, et al (2020). Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: single-center experience. *Pediatr Transplant* 2020;24:e13723. Retrieved from: <https://onlinelibrary.wiley.com/doi/10.1111/ptr.13723>

- Single-center, retrospective review of the incidence and outcomes of PTLD in 173 patients who underwent intestinal transplant with or without liver who received alemtuzumab, rATG, or anti-IL-2R medications. 30 cases of PTLD occurred in 28 patients. PTLD was more common in patients receiving alemtuzumab or anti-IL-2R medications as compared to rATG, though this did not reach statistical significance. A majority of patients received resection and/or rituximab as treatment and outcomes were better than more severe cases requiring chemotherapy. The authors concluded that overimmunosuppression with alemtuzumab increases the risk of development of PTLD in pediatric intestinal transplant recipients.

Allen UP, et al (2019). Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. 2019;33:e13652. Received from: <https://pubmed.ncbi.nlm.nih.gov/31230381/>

- Guidelines for the management of EBV viremia and PTLD in solid organ transplant recipients.

L'Huillier AG, et al (2019). Posttransplant lymphoproliferative disorder in pediatric patients: Survival rates according to primary sites of occurrence and a proposed clinical categorization. *Am J Transplant*. 2019;19(10):2764-2774. Retrieved from: <https://www.ncbi.nlm.nih.gov/pubmed/30884098>

- Retrospective study of 82 pediatric solid organ transplant recipients with PTLD.

Weintraub L, et al (2014). Identifying Predictive Factors for Posttransplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients With Epstein-Barr Virus Viremia. *J Pediatr Hematol Oncol*. 2014; 36(8):e481-486. Retrieved from: <https://insights.ovid.com/article/00043426-201411000-00025>.

- Retrospective analysis of 350 pediatric solid organ transplant recipients seeking to identify predictive risk factors of development of PTLD in patients with EBV viremia. Identified risk factors include: younger age at time of transplant, increased immunosuppression prior to EBV viremia, higher peak EBV, and presence of symptoms.

Schober T, et al (2013). Characteristics of Early and Late PTLD Development in Pediatric Solid Organ Transplant Recipients. *Transplantation*. 2013;95:240-246. Retrieved from: <https://insights.ovid.com/crossref?an=00007890-201301150-00035>.

- Review of German multicenter pediatric PTLD registry data including 127 patients. Evaluates characteristics of patients who developed early and late PTLD.

### 11.7.3 Pharmacogenomics

Alghamdi A, et al. (2023) Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients. *Clin Transl Sci*. 2023;16(10):1768-1778. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/37340713/>.

- Retrospective review assessing tacrolimus pharmacokinetics and toxicity based on CYP3A5 polymorphism, age, and concomitant fluconazole

Min S, et al (2022). An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients. *Transplantation*. 2022;106(3):597-606. Retrieved from: [https://journals.lww.com/transplantjournal/Fulltext/2022/03000/An\\_Integrated\\_Clinical\\_and\\_Genetic\\_Prediction.28.aspx](https://journals.lww.com/transplantjournal/Fulltext/2022/03000/An_Integrated_Clinical_and_Genetic_Prediction.28.aspx)

- A genome-wide association study that highlights the importance of incorporating age, organ type, and genotype in predicting tacrolimus levels